WO1996003997A3 - Treatment of cancer using hsv mutant - Google Patents

Treatment of cancer using hsv mutant Download PDF

Info

Publication number
WO1996003997A3
WO1996003997A3 PCT/GB1995/001791 GB9501791W WO9603997A3 WO 1996003997 A3 WO1996003997 A3 WO 1996003997A3 GB 9501791 W GB9501791 W GB 9501791W WO 9603997 A3 WO9603997 A3 WO 9603997A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
mutant
treatment
hsv mutant
gene
Prior art date
Application number
PCT/GB1995/001791
Other languages
French (fr)
Other versions
WO1996003997A2 (en
Inventor
Alasdair Roderick Maclean
Susanne Moira Brown
Nigel William Fraser
Bruce Paul Randazzo
Original Assignee
Medical Res Council
Wistar Inst
Alasdair Roderick Maclean
Susanne Moira Brown
Nigel William Fraser
Bruce Paul Randazzo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10759079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1996003997(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP95927034A priority Critical patent/EP0773785B1/en
Priority to DE69527204T priority patent/DE69527204T2/en
Priority to AT95927034T priority patent/ATE219681T1/en
Priority to DK95927034T priority patent/DK0773785T3/en
Priority to CA2196315A priority patent/CA2196315C/en
Application filed by Medical Res Council, Wistar Inst, Alasdair Roderick Maclean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo filed Critical Medical Res Council
Priority to AU31199/95A priority patent/AU3119995A/en
Priority to JP50630496A priority patent/JP4321723B2/en
Publication of WO1996003997A2 publication Critical patent/WO1996003997A2/en
Publication of WO1996003997A3 publication Critical patent/WO1996003997A3/en
Priority to US11/152,591 priority patent/US7674468B2/en
Priority to US12/692,347 priority patent/US8067012B2/en
Priority to US13/305,516 priority patent/US20120141418A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the η34.5 gene in the long repeat region (RL) such that the η34.5 gene is non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
PCT/GB1995/001791 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant WO1996003997A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP50630496A JP4321723B2 (en) 1994-07-29 1995-07-28 Treatment of cancer with HSV mutants
DE69527204T DE69527204T2 (en) 1994-07-29 1995-07-28 TREATING CANCER BY USING HSV MUTANTS
AT95927034T ATE219681T1 (en) 1994-07-29 1995-07-28 TREATING CANCER BY USING HSV MUTANTS
DK95927034T DK0773785T3 (en) 1994-07-29 1995-07-28 Treatment of cancer ced using HSV mutant
CA2196315A CA2196315C (en) 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant
EP95927034A EP0773785B1 (en) 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant
AU31199/95A AU3119995A (en) 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant
US11/152,591 US7674468B2 (en) 1994-07-29 2005-06-13 Treatment of cancer using HSV mutant
US12/692,347 US8067012B2 (en) 1994-07-29 2010-01-22 Treatment of melanoma using HSV mutant
US13/305,516 US20120141418A1 (en) 1994-07-29 2011-11-28 Treatment of Melanoma Using HSV Mutant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9415320A GB9415320D0 (en) 1994-07-29 1994-07-29 Cancer treatment
GB9415320.2 1994-07-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08776350 A-371-Of-International 1995-07-28
US11/152,591 Continuation US7674468B2 (en) 1994-07-29 2005-06-13 Treatment of cancer using HSV mutant

Publications (2)

Publication Number Publication Date
WO1996003997A2 WO1996003997A2 (en) 1996-02-15
WO1996003997A3 true WO1996003997A3 (en) 1996-05-02

Family

ID=10759079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001791 WO1996003997A2 (en) 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant

Country Status (12)

Country Link
US (3) US7674468B2 (en)
EP (2) EP1192948A3 (en)
JP (2) JP4321723B2 (en)
AT (1) ATE219681T1 (en)
AU (1) AU3119995A (en)
CA (1) CA2196315C (en)
DE (1) DE69527204T2 (en)
DK (1) DK0773785T3 (en)
ES (1) ES2179880T3 (en)
GB (1) GB9415320D0 (en)
PT (1) PT773785E (en)
WO (1) WO1996003997A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
IL118942A (en) * 1995-07-27 2002-09-12 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines
ATE241994T1 (en) * 1996-01-25 2003-06-15 Univ Glasgow HSV-MUTANT-1716 FOR THE TREATMENT OF MESOTHELIOMA
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
EP1212428B1 (en) * 1999-08-31 2004-12-01 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
DE60026554T2 (en) 1999-09-17 2006-09-28 Wellstat Biologics Corp. ONCOLYTIC VESICULAR STOMATITIS VIRUS
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
CA2441663C (en) 2001-03-27 2013-01-22 Medigene, Inc. Viral vectors and their use in therapeutic methods
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (en) * 2002-05-02 2004-04-02 Keio Gijuku Antitumor agent using hsv
RU2362584C2 (en) 2003-03-07 2009-07-27 Робартс Рисерч Инститьют Application of myxoma virus for therapeutic treatment of cancer and chronic virus infection
NZ542902A (en) 2003-03-27 2007-06-29 Ottawa Health Research Inst Mutant vesicular stomatitis viruses and use thereof
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
EP1694852B1 (en) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
EP2388315B1 (en) 2005-03-07 2014-05-21 The University of Western Ontario Use of a Myxoma virus that does not express functional M135R for therapeutic treatment
CN105769931B (en) 2006-09-15 2021-04-27 渥太华医院研究机构 Oncolytic rhabdovirus
JP6802275B2 (en) * 2016-04-22 2020-12-16 イムヴィラ・カンパニー・リミテッドＩｍｍｖｉｒａ Ｃｏ．， Ｌｉｍｉｔｅｄ Construction of oncolytic herpes simplex virus (oHSV) obligate vector and its constructs for the treatment of cancer
WO2022048631A1 (en) * 2020-09-04 2022-03-10 上海翊石医药科技有限公司 Compound having antitumor activity and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013943A1 (en) * 1991-01-31 1992-08-20 Smithkline Beecham Biologicals S.A. Herpes simplex virus-1 deletion variants and vaccines thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
WO1993019591A1 (en) 1992-03-31 1993-10-14 Arch Development Corporation Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
CA2234060A1 (en) 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
ATE241994T1 (en) * 1996-01-25 2003-06-15 Univ Glasgow HSV-MUTANT-1716 FOR THE TREATMENT OF MESOTHELIOMA
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
EP1694852B1 (en) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
WO2007026146A1 (en) 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2007132169A1 (en) 2006-05-11 2007-11-22 Crusade Laboratories Limited Mutant hsv, materials and methods for generation of mutant hsv
US8163292B2 (en) 2007-02-16 2012-04-24 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013943A1 (en) * 1991-01-31 1992-08-20 Smithkline Beecham Biologicals S.A. Herpes simplex virus-1 deletion variants and vaccines thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOVIATSIS, E.J. ET AL.: "ANTITUMOR ACTIVITY AND REPORTER GENE TRANSFER INTO RAT BRAIN NEOPLASMS INOCULATED WITH HERPES SIMPLEX VIRUS VECTORS DEFECTIVE IN THYMIDINE KINASE OR RIBOUCLEOTIDE REDUCTASE", GENE THERAPY, vol. 1, pages 323 - 331, XP000867507 *
CHOU, J. ET AL.: "MAPPING OF HERPES SIMPLEX VIRUS-1 NEUROVIRULENCE TO GAMMA-1 34.5, A GENE NONESSENTIAL FOR GROWTH IN CULTURE", SCIENCE, vol. 250, pages 1262 - 1266, XP002018560 *
MARKERT, J.M. ET AL.: "Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir", NEUROSURGERY, vol. 32, pages 597 - 603, XP002090036 *
TAHA, M.Y. ET AL.: "A VARIANT OF HERPES SIMPLEX VIRUS TYPE 2 STRAIN HG52 WITH A 1.5 KB DELETION IN TL BETWEEN 0 TO 0.02 AND 0.81 TO 0.83 MAP UNITS IS NON-NEUROVIRULENT FOR MICE", JOURNAL OF GENERAL VIROLOGY, vol. 70, pages 705 - 716, XP000560886 *

Also Published As

Publication number Publication date
PT773785E (en) 2002-11-29
ATE219681T1 (en) 2002-07-15
JP2008037869A (en) 2008-02-21
CA2196315C (en) 2010-02-09
US7674468B2 (en) 2010-03-09
AU3119995A (en) 1996-03-04
EP1192948A2 (en) 2002-04-03
DE69527204D1 (en) 2002-08-01
US8067012B2 (en) 2011-11-29
US20050260169A1 (en) 2005-11-24
EP0773785A2 (en) 1997-05-21
ES2179880T3 (en) 2003-02-01
WO1996003997A2 (en) 1996-02-15
JPH10503766A (en) 1998-04-07
DK0773785T3 (en) 2002-10-07
EP1192948A3 (en) 2002-09-04
EP0773785B1 (en) 2002-06-26
US20100172872A1 (en) 2010-07-08
JP4321723B2 (en) 2009-08-26
CA2196315A1 (en) 1996-02-15
GB9415320D0 (en) 1994-09-21
US20120141418A1 (en) 2012-06-07
DE69527204T2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
WO1996003997A3 (en) Treatment of cancer using hsv mutant
LUC00032I2 (en)
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
AU7264694A (en) Defective adenovirus vectors and use thereof in gene therapy
GB2353529B (en) Mutant herpes simplex viruses and uses thereof
WO1996040055A3 (en) Biological agent compositions
BG101972A (en) Dosage fixing inhaler for fluticazon propionate
AU7693396A (en) Poly(9,9'-spiro-bisfluorenes), the production and use of same
AU4167493A (en) Polyfluorohydrocarbon group-containing acrylates, their polymers and applications of the polymers
AU3607693A (en) Iris dilator, deformer and procedure
HK1026913A1 (en) Ligand for herpes simplex virus entry mediator and methods of use
NZ305188A (en) DNA encoding Human Papilloma Virus (hPV)type 18
WO1997012963A3 (en) A paf-acetylhydrolase and use in therapy
AU6910991A (en) The scl gene, and the encoded hematopoietic factor
AU7138091A (en) Fluorourethane group-containing polymers made from ethylenically unsaturated monomers, process for their preparation and their use
GB2359083A (en) Mutant herpes simplex viruses and uses thereof
AU6163590A (en) Mutant pseudorabies virus, and vaccines containing the same
MX9700298A (en) Adenovirus comprising a gene coding for an no synthase.
WO1998017231A3 (en) Treatment and delivery of hydroxychloroquine
GR960100092A (en) Garlic-based pharmaceutical preparation against simplex and genitalis herpes
MXPA02000485A (en) 2-amino-benzoxazinones for the treatment of herpes simplex virus.
Pepper The effects of goal specificity, goal difficulty and goal source on endurance performance
AU4398397A (en) Microorganism of the genus (ascochyta) and use thereof
UA32057A (en) Method for treating keratouveites of various etiology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2196315

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995927034

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 776350

Country of ref document: US

Date of ref document: 19970418

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995927034

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1995927034

Country of ref document: EP